Apellis Pharmaceuticals (APLS +4.4%) is up on below-average volume on the heels of its announcement that enrollment has been completed (80 subjects) in its Phase 3 PEGASUS study evaluating lead candidate APL-2 (pegcetacoplan), compared to Alexion’s Soliris (eculizumab), in patients with paroxysmal nocturnal hemoglobinuria (PNH).
About half of the participants are transfusion-dependent. Topline results should be available in December.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.